GlassScriptPhysician profile
Amy D Rapp
NPI 1184726580
$1,638.68
in general payments reported to CMS, 2019-2025
26 companies · $540 in 2025
The $540 reported for 2025 was more than what 81% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.85 · 2022: $178 · 2023: $429 · 2024: $448 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $194.73 | 2023-2025 | Briviact |
| Medtronic, INC. | $168.72 | 2023 | Mazor X System |
| Neurocrine Biosciences, INC. | $161.64 | 2024-2025 | Ingrezza |
| Abbvie INC. | $113.74 | 2025 | |
| Jazz Pharmaceuticals INC. | $112.68 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $87.80 | 2024 | Austedo Xr, Ajovy |
| Boston Scientific Corporation | $86.59 | 2021-2025 | Infinion 16 |
| Providence Medical Technology, INC. | $76.72 | 2023 | |
| Abbott Laboratories | $73.77 | 2022-2024 | Proclaim |
| Arbor Pharmaceuticals, INC. | $71.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.93 | 2024-2025 | Hyqvia |
| Stryker Corporation | $52.93 | 2025 | N/A |
| Lundbeck LLC | $48.38 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $42.34 | 2023 | Sunosi |
| Acadia Pharmaceuticals INC | $41.44 | 2025 | Nuplazid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $41.37 | 2023 | Ultomiris, Soliris |
| Azurity Pharmaceuticals, INC. | $36.72 | 2023 | Gliadel |
| Amgen INC. | $23.69 | 2025 | |
| Kls-Martin L.P. | $23.60 | 2022 | |
| Pfizer INC. | $19.62 | 2023 | |
| Janssen Biotech, INC. | $18.84 | 2025 | |
| Heron Therapeutics, INC. | $18.32 | 2025 | Zynrelef |
| Argenx US, INC. | $16.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.11 | 2025 | Wainua |
| Tanabe Pharma America, INC. | $14.47 | 2024 | |
| Integra Lifesciences Corporation | $14.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.